Additionally, liquid biopsy has also proved to be useful for the identification of biomarkers associated with cyclin-dependent kinase inhibitors (CDKi) resistance and for predicting the subsequent development of metastatic disease, in hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer patients. Here, ERBB2 is linked to metastatic neoplasm.